02591.HK
Guangzhou Innogen Pharmaceutl Grp Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.60
−0.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 206.3M | 128.1M | — | — | — |
| Cost of Revenue | 49.5M | 23.7M | 17.3M | 19.6M | 19.1M |
| Gross Profit | 156.7M | 104.4M | (17.3M) | (19.6M) | (19.1M) |
| Operating Expenses | |||||
| R&D Expense | 326.2M | 194.3M | 102.5M | 492.1M | 272.3M |
| SG&A Expense | 364.1M | 244.0M | 40.2M | 11.3M | 36.1M |
| General & Admin Expense | — | — | 37.8M | 11.3M | — |
| Selling & Marketing Expense | — | — | 2.4M | — | — |
| Other Expenses | 1.5M | — | 13.6M | 243.4M | — |
| Total Operating Expenses | 691.8M | 438.3M | 156.4M | 746.8M | 308.4M |
| Cost and Expenses | 741.4M | 462.0M | 189.4M | 746.8M | 327.4M |
| Operating Income (EBIT) | (535.1M) | (333.9M) | (189.4M) | (746.8M) | (327.4M) |
| Non-Operating | |||||
| Interest Income | 29.2M | 13.1M | 3.8M | 4.2M | 2.8M |
| Interest Expense | 4.2M | 1.7M | 873.0K | 2.3M | 2.6M |
| Net Interest Income | 25.0M | 11.5M | 2.9M | 1.9M | 182.8K |
| Other Non-Op Income/Expense | (15.3M) | 1.4M | 14.7M | 13.5M | 20.5M |
| Non-Operating Income (excl Interest) | 17.1M | — | — | — | — |
| EBT (Pre-Tax Income) | (550.4M) | (332.5M) | (174.7M) | (733.4M) | (307.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (550.4M) | (332.5M) | (174.7M) | (733.4M) | (307.0M) |
| Earnings from Cont. Ops | (550.4M) | (332.5M) | (174.7M) | (733.4M) | (307.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (550.4M) | (332.5M) | (174.7M) | (733.4M) | (307.0M) |
| Per Share | |||||
| Basic EPS | (HK$1.25) | (HK$0.76) | (HK$0.38) | (HK$1.61) | (HK$0.68) |
| Diluted EPS | (HK$1.25) | (HK$0.76) | (HK$0.38) | (HK$1.60) | (HK$0.68) |
| Revenue Per Share | HK$0.45 | HK$0.30 | HK$0.00 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 456.8M | 434.1M | 456.8M | 456.8M | 456.8M |
| Diluted Shares Outstanding | 456.8M | 434.1M | 456.8M | 456.8M | 456.8M |
| Profitability Metrics | |||||
| EBITDA | (527.9M) | (324.3M) | (156.9M) | (711.4M) | (308.4M) |
| D&A | 24.3M | 9.6M | 16.9M | 19.6M | 19.1M |
| EBIT | (552.2M) | (333.9M) | (173.8M) | (731.1M) | (327.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026